United States of America. The Food and Drug Administration and the United States Pharmacopeia have recently received reports noting confusion between Soriatane (acitretin) Capsules and Loxitane (loxapine) Capsules.
Soriatane is a retinoid that is indicated for severe psoriasis. Because of its teratogenic potential, Soriatane should be prescribed only by physicians who have special competence in the diagnosis and treatment of severe psoriasis, are experienced in the use of systemic retinoids, and understand the risk of teratogenicity.
Loxitane is indicated for the management of the manifestations of psychotic disorders. It has been available for a number of years and is currently also available generically. The confusion occurs because, when written, a cursive “S” and “L” and small “ri” and “xi” may look similar. The fact that the two products are available in the same two strengths (10 mg and 25 mg) and dosage form (capsule) has created the possibility for a serious dispensing error.
Reference: MedWatch - Important prescribing notice, September 1998 [http://www.fda.gov/medwatch/safety/1998/soriat.htm].